This doesn't mean that anyone else can start using it. It applies only to the name 'Livimmune'. The worst that would happen is we may need to change the name of this board. 😂 (just kidding!)

This is what AI had to say about this.

The Livimmune trademark expiring (or running out of extensions) does not allow any other company to use, manufacture, or run clinical trials with leronlimab. A trademark has nothing to do with drug patents, regulatory exclusivity, or manufacturing rights. It only protects the brand name.

Below is the clear breakdown, grounded in the USPTO record for LIVIMMUNE.

✔ What the 7‑month trademark deadline actually means

The USPTO shows LIVIMMUNE is in “Fourth Extension – Granted” status under an Intent‑to‑Use application.
This means:

• Cytodyn has not yet proven commercial use of the trademark.
• They have been granted multiple 6‑month extensions.
• They have about 7 months left to either:
  • Show actual commercial use of the name LIVIMMUNE, or
  • Request another extension (if eligible), or
  • Let the trademark application go abandoned.

If the trademark lapses, only the brand name is affected.
It does not affect ownership of leronlimab as a molecule.

✔ Can another company start using the name “Livimmune”?

Not while the trademark application is active.
If Cytodyn fails to show use and the application becomes abandoned, then another company could theoretically file for the trademark “Livimmune.”

But this would only give them rights to the name, not the drug.

✔ Can another company start using leronlimab in clinical trials?

No.
A trademark expiration does not give anyone rights to:

• The molecule (leronlimab)
• The underlying patents
• The FDA IND (Investigational New Drug) authorization
• The clinical data package
• The manufacturing process

To run clinical trials on leronlimab, a company must have:

1. Patent rights or a license
2. Control of the IND
3. Access to the drug substance and drug product
4. CMC (chemistry, manufacturing, controls) documentation

None of these are affected by a trademark.

✔ Can another company start manufacturing leronlimab?

No — not legally.
Manufacturing a biologic like leronlimab requires:

• Patent rights
• Trade‑secret manufacturing know‑how
• FDA‑approved facilities
• Access to the proprietary cell line
• Regulatory documentation

Even if the trademark expires, the cell line and manufacturing process remain protected as trade secrets, and the patents remain in force until their expiration dates.

✔ Why trademarks don’t matter for drug ownership

A drug can be sold under many names (brand, generic, internal code).
The trademark only protects the marketing name.

Examples:

• “Keytruda” is a trademark; pembrolizumab is the drug.
• “Livimmune” is a trademark; leronlimab is the drug.

Losing the trademark does not allow anyone else to make pembrolizumab — or leronlimab.

🧭 Bottom line

• The 7‑month trademark clock only affects the name LIVIMMUNE, not leronlimab itself.
• No other company can legally run trials or manufacture leronlimab without Cytodyn’s patents, IND, and proprietary manufacturing rights.
• If the trademark lapses, another company could only take the name, which is meaningless without the drug.